AMPE stock drops amid plans to end studies for COVID-19 therapy (NYSE:AMPE)
seekingalpha.com
finance
2022-06-02 21:05:23

wildpixel/iStock via Getty Images Ampio Pharmaceuticals (NYSE:AMPE), a company focused on immunomodulatory therapies, is trading lower in the post-market Thursday as investors react to its plans to discontinue the COVID-19 program for experimental therapy Ampion. Issuing a letter to shareholders, Ampion (AMPE) Chief Executive Mike Martino noted that as previous announced in May, the program consisting of three clinical trials; AP-017, AP-018 and AP-019 failed to show a clinically meaningful treatment effect.
